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Background: This study was done to compare the efﬁcacy of a recently developed eosinophil-derived
neurotoxin (EDN) ELISA kit (“BioTracer™ K® EDN ELISA Kit”) to a commercially available EDN ELISA
kit (“MBL EDN ELISA Kit”) and demonstrate the usefulness of serum EDN measurement in young asth-
matic children.
Methods: Forty-eight children with physician-diagnosed asthma (Asthma group) and 31 age-matched
normal controls (Control group) were recruited from the Asthma and Allergy Center at Inje University
Sanggye Paik Hospital, Seoul, Korea from January 2010 to September of 2012. EDN levels in each serum
specimenwere measured 2 times using the: 1) BioTracer™ K® EDN ELISA Kit and 2) MBL EDN ELISA Kit at
the Inje University Sanggye Paik Hospital laboratory. EDN level measurements in each serum specimen
were compared.
Results: EDN measurements from the BioTracer™ K® EDN ELISA Kit correlated well with those from the
MBL EDN ELISA Kit: r ¼ 0.9472 at the Inje University Sanggye Paik Hospital laboratory. These r values
were considered both clinically relevant (i.e., r > 0.85) and statistically signiﬁcant (p < 0.0001). EDN
measurements from both kits positively correlated with asthma symptom severity (p < 0.0001). No
serious adverse events occurred during the study.
Conclusions: The BioTracer™ K® EDN ELISA Kit was accurate and useful in measuring EDN levels in young
asthma patient serum. Because of our kit's distinct advantages and utility, we suggest this kit can be used
for the timely diagnosis, treatment, and monitoring of asthma in asthma patients of all ages, especially
those too young to perform pulmonary function tests.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The eosinophil is a major player in allergic disease.1 Therefore,
direct measurement of eosinophilic inﬂammation is needed for
diagnosis, treatment, and monitoring of asthma. However, man-
agement decisions have traditionally been based on symptoms
(non-speciﬁc and subjective), airway function, and rescue medi-
cation use.2,3
The current feeling on eosinophilic inﬂammation monitoring is
that eosinophil counts/percentages provide only a limitedInje University Sanggye Paik
9-707, South Korea.
ety of Allergology.
rgology. Production and hosting by Elseunderstanding of the activity of these cells, whereas, the secretory
activity of eosinophils (the product of the concentration of eosin-
ophils and their propensity to release mediators)4 provides a more
accurate and complete picture.
During the past few decades, speciﬁc markers have been iden-
tiﬁed that are currently used to identify the activity and turnover of
the eosinophil. The most promising of these markers has been
eosinophil-derived neurotoxin (EDN), which has been studied in a
number of inﬂammatory diseases including asthma.5e8 An
enzyme-linked immunosorbent assay (ELISA) kit for measuring
EDN has been available for more than ten years (MBL International
Corporation, Woburn, MA); however, its utility is limited. The
Ministry of Food and Drug Safety (MFDS) in Korea allows this
product to be used only for research purposes (MBL Code No 7630)9
and therefore cannot be used in routine clinical practice such asvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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especially those too young to participate in lung function tests (i.e.,
under 7 years of age).
The purpose of this study was to investigate the efﬁcacy and
utility of a recently developed EDN ELISA kit (referred to hereafter
as “BioTracer™ K® EDN ELISA Kit”) for the diagnosis, treatment, and
monitoring of asthma patients in Korea. The BioTracer™ K® EDN
ELISA Kit was directly compared to a commercially available EDN
ELISA kit (referred to hereafter as “MBL EDN ELISA Kit”) in Korea.
Methods
Development of EDN antibody
Female BALB/c mice (6e8 weeks old) were injected intraperi-
toneally with 50e100 mg of natural EDN antigen (Mayo Clinic,
Rochester, MN, USA) in Freund's complete adjuvant (Sigma, St.
Louis, MO, USA). Booster injections of 50e100 mg of antigen were
administered every 2e3 weeks either in incomplete adjuvant or in
PBS. After the ﬁnal injection, antibody formation was checked by
eye bleeding. Once veriﬁed, 100e200 mg of antibody was injected
3e4 consecutive days before fusion.
Mice were sacriﬁced by cervical dislocation and brieﬂy
immersed in 70% alcohol to sterilize. The spleen was removed,
spleen cells were ﬂushed and harvested by centrifuge, then
resuspended in serum-free media. Spleen cells were fused with
myeloma cells from the P3X63Ag8.653 mouse cell line (Sigma) at a
ratio of 1.5:1.1. Hybridomas were selected by ELISA for antibody
formation. Monoclonal anti-EDN antibody from the mice was then
puriﬁed by centrifuge and stored at 4 C (short-term storage) or
at 20 C (long-term storage).
Sandwich ELISA
The BioTracer™ K® EDN ELISA Kit measured human EDN by
sandwich ELISA.10 This ELISA detects human EDN with a mini-
mum detection limit of 6.0 ng/ml, maximum detection limit of
400 ng/ml, and does not cross-react with eosinophil cationic
protein (ECP). The method described by Morioka et al.11 was
followed but modiﬁed slightly. Brieﬂy, Nunc MaxiSorp 96-well
plates (Thermo Fisher Scientiﬁc, Waltham, MA, USA) were
coated overnight at 4 C with 100 ml of mouse anti-EDN mono-
clonal antibody (mAb), diluted in phosphate buffer solution
(PBS). The wells were blocked overnight at 4 C with 200 ml of
blocking buffer (1X PBS, 1% bovine serum albumin (BSA), 10%
sucrose). Standard EDN was diluted with 50 mM tris pH8.0
containing 0.05% Tween 20 buffer (SigmaeAldrich, St. Louis, MO,
USA), 0.15 M NaCl, and 0.5% BSA (termed assay diluent). The
range of measurements was 0.6e40 ng/ml, indicating assay
sensitivity was less than 0.6 ng/ml. Between each subsequent
step, plates were washed three times in PBS containing 0.05%
Tween 20. Samples were then diluted in 50 mM tris pH8.0
containing 0.05% Tween 20, and 0.15 M NaCl. One-hundred
microlitre of standards and diluted samples were applied to the
plates, and incubated at room temperature for 1 h. After washing,
100 ml of horseradish-peroxidase-labeled mouse anti-EDN mAb
was added to the wells and incubated at room temperature for
1 h. After another washing, the peroxidase substrate tetrame-
thylbenzidine (TMB) (SigmaeAldrich) was added (100 ml/well)
and incubated for 10 min at room temperature. Enzyme reactions
were stopped with 1 N HCl (100 ml/well). Absorbance was
measured at 450 nm by a Micro Plate Reader Inﬁnite 200 PRO
(TECAN, M€annedorf, Switzerland). Serum EDN was determined
from a dose response curve by multiplying the value read from
the standard curve by the dilution factor.Subjects
Forty-eight children with physician-diagnosed asthma (Asthma
group) and 31 age-matched normal controls (Control group) were
recruited from the Asthma and Allergy Center at Inje University
Sanggye Paik Hospital, Seoul, Korea from January 2010 to
September of 2012. The Asthma group consisted of 29 boys and 19
girls (mean age, 3.2 years; range, 1.4e5.6 years). All children in this
group had previously been diagnosed as having asthma according
to the Global Initiative for Asthma (GINA) guidelines.2 Infantile
asthma was originally diagnosed as having more than three
wheezing episodes. They had been using bronchodilators on de-
mand during symptomatic periods.
Asthma symptom severity was based on a previously published
asthma scoring system for young children.12 All clinical character-
istics were scored on a 3-point ordinal scale (0, 1, and 2), with the
total score consisting of ﬁve clinical features: (1) respiratory rate
(<40 breaths/min, 40e60 breaths/min, >60 breaths/min); (2)
wheezing (expiratory or inspiratory wheezing heard with a
stethoscope); (3) retraction (subcostal or intercostals muscle
retraction); (4) observed dyspnea (observer's impression of the
patient's degree of breathlessness); and (5) inspiratory to expira-
tory ratio (I > E, I ¼ E, I < E). All ﬁve characteristics were weighted
equally with ﬁnal clinical scores obtained by summing individual
item values for a maximum possible clinical asthma score of 10.
Patients were then grouped according to their total score: a score of
0 was considered “symptom free”; scores of 1e3 were considered
“Mild”; scores of 4e6 were labeled “Moderate”; and scores of 7e9
were grouped as “Severe”. These asthma scores were then
compared to serum EDN levels to determine if there were any
correlations between them.
Inclusion criteria included symptomatic or asymptomatic
asthma. Exclusion criteria included: any antibiotic treatment or
other respiratory medicine within 4 weeks of patient enrollment;
any health condition that would affect the ability of the patient to
give a blood specimen; or any potential for serious adverse events.
The Control group consisted of 18 boys and 13 girls (mean age,
3.1 years; range, 1.3e5.4 years). None had a history of asthma or
allergic disease or an identiﬁable airway infection within the 4
weeks prior to the study.
The primary outcome was EDN level measurements in all pa-
tient serum specimens comparing results found with the Bio-
Tracer™ K® EDN ELISA Kit to results found in theMBL EDN ELISA Kit
at Inje University Sanggye Paik Hospital (Seoul, Korea). All adverse
events, including local and systemic reactions, were also recorded.
Legal guardians of all participants gavewritten informed consent
and patient anonymity was preserved using methods approved by
the Ethics Committee. This study was approved by the Inje Univer-
sity Sanggye Paik Hospital Institutional Review Board (IRB).
Specimen collection and measurements
Blood specimen collection
BD Vacutainer (Becton, Dickinson and Company, Franklin Lakes,
NJ, USA) serum separation tubes were used to collect blood speci-
mens. The tourniquet was removed from the arm as soon as blood
ﬂowed to prevent hemoconcentration. Care was taken to perform
venipuncture in a manner so that the likelihood of any complica-
tion following this was minimized. The nurse performing the
venipuncture observed universal precautions for the prevention of
bloodborne pathogen transmission.
Serum specimen collection
Serum specimens were prepared as described by Peterson
et al.13 Brieﬂy, serum was prepared by allowing blood to clot at
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serum specimen was aliquoted into a new plastic tube and stored
at 70 C until the assay.Serum EDN measurement
The central laboratory at Inje University Sanggye Paik Hospital
in Seoul, Korea was used for serum EDN measurements. Each
sample was measured two separate times for EDN level: once by
the BioTracer™ K® EDN ELISA Kit and once by the MBL EDN ELISA
Kit at Inje University Sanggye Paik Hospital.Fig. 1. Correlations between EDN measurements using the BioTracer™ K® EDN ELISA
Kit and the MBL EDN ELISA Kit at Inje University Sanggye Paik Hospital laboratory
(r ¼ 0.9472). These r values were considered both clinically relevant (i.e., r > 0.85) and
statistically signiﬁcant (p < 0.0001).Statistical analysis
All demographic data are presented as median [25th percentile,
75th percentile], unless otherwise noted.
As all EDN level data were nonparametric, screening of data for
differences in EDN levels between the two groups was performed
using the ManneWhitney U test. Spearman correlation coefﬁcients
were used for analyzing correlations of EDN levels between the two
kits, BioTracer™ K® EDN ELISA and MBL EDN ELISA. A positive
Spearman correlation coefﬁcient r of >0.85 was considered clini-
cally relevant and p values <0.05 were considered statistically
signiﬁcant.Results
Subject measurements
Demographic data
All demographic data were as follows: Total number of subjects
(n), n ¼ 79; Age (yr) median [25th percentile, 75th percentile], 3
[1.5, 5]; Male:Female, 47:32.Human EDN concentration in Asthma and Control groups
Serum samples from the Asthma and Control groups were
measured with the BioTracer™ K® EDN ELISA Kit and minimum
and maximum EDN levels, 25th percentile, 75th percentile, me-
dian, mean and standard deviations were determined (Table 1).
All EDN level data were nonparametric; consequently, they are
stated as median [25th percentile, 75th percentile] in ng/ml. Using
the BioTracer™ K® EDN ELISA Kit, EDN levels for 79 subjects were
50.60[34.05, 83.05]. No serious adverse events occurred during
the study.Correlations between EDN measurements
EDN measurements using the BioTracer™ K® EDN ELISA Kit
correlated well with measurements from the MBL EDN ELISA Kit:
r ¼ 0.9611 at the Inje University Sanggye Paik Hospital laboratory
(Fig. 1). This r value was considered both clinically relevant (i.e.,
r > 0.85) and statistically signiﬁcant (p < 0.0001).Table 1
Serum EDN concentration in asthma and normal controls.
Asthma group (n ¼ 48) Control group (n ¼ 31)
Minimum 37.30 8.000
25% Percentile 50.55 26.70
Median 73.75 31.90
75% Percentile 98.55 34.75
Maximum 168.1 65.00
Mean 77.33 31.51
SD 30.17 12.34
Median þ 1SD 103.92 44.24
SD, Standard Deviation.Correlations between EDN levels and asthma symptom severity
EDNmeasurements taken by both kits positively correlatedwith
asthma symptom scores (p < 0.0001). 26.7% of subjects were
symptom free (score ¼ 0), while 48.9% were in the Mild subgroup
(score ¼ 1e3) and 24.4% were in the Moderate subgroup
(score ¼ 4e6). There were no patients in the Severe subgroup
(score ¼ 7e9).
Standard curve for EDN
A typical standard curve for EDN is shown in Figure 2. EDN
concentrations in specimens were determined by multiplying the
value read from the standard curve by the dilution factors. EDN
measurements ranged from 0.60 to 40.0 ng/ml, indicating that
assay sensitivity was less than 0.60 ng/ml.
Assay measurements
Assay precision
Intraassay precision (Table 2) was determined by repetitive
measurements (8 times) of 3 different serum specimens. Interassay
precision (Table 2) was determined by comparing 3 other different
serum specimens from 10 independent assays performed on 10
different days.
Dilution test
Good linearity was noted with 3 different serum specimens that
were serially diluted (Fig. 3). Dilution factors were 0.03125, 0.0625,
0.125, 0.25, 0.5, and 1.0.Fig. 2. Standard curve for EDN.
Table 2
Assay precision.
Sample Replicates Mean (ng/ml) SD (ng/ml) CV (%)
Intraassay 1 8 0.93 0.04 4.1
2 8 3.73 0.07 1.9
3 8 9.02 0.22 2.4
Interassay 4 10 4.67 0.40 8.6
5 10 14.26 1.04 7.3
6 10 18.52 1.35 7.3
Fig. 3. Dilution test.
Fig. 4. Cross-reactivity for ECP.
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Three different specimens supplemented with different
amounts of puriﬁed EDN (2.0, 4.0, and 8.0 ng/ml, respectively) were
used to determine the ratio of recovered/added EDN concentra-
tions, expressed as percentages. As seen in Table 3, recoveries of
puriﬁed EDN added to serum specimens ranged from 90 to 109%.Cross-reactivity test
To determine if there was any cross-reactivity with ECP when
using the BioTracer™ K® EDN ELISA Kit, two separate tests were
conducted. First, as increasing amounts of ECP antigen were added
to eachwell (negative, positive, 0, 0.4,1.2, 4,12, and 40 ng/ml), there
was no corresponding increase in optical density (O.D), as
measured by the BioTracer™ K® EDN ELISA Kit [(O.D1 ¼ 0.058,
0.054, 0.052, 0.054, 0.054, 0.060, 0.054, 0.064) and duplicate results
(O.D2 ¼ 0.052, 0.051, 0.054, 0.051, 0.053, 0.053, 0.062, 0.064)].
Second, much larger amounts of ECP antigen (0, 50, 100, 500, 1000,
and 10,000 ng/ml) were added to wells with no corresponding
increase in O.D, as measured by the BioTracer™ K® EDN ELISA Kit
(0.054, 0.058, 0.052, 0.060, 0.078, and 0.083). EDN antigenwas then
added to each well (0.0, 0.6, 1.2, 2.5, 5.0, 10, 20, and 40 ng/ml) and
O.D did increase correspondingly (0.052, 0.104, 0.159, 0.308, 0.577,
1.101, 1.720, and 1.974). The results of these two tests for cross-
reactivity were combined in Figure 4.Table 3
Recovery test.
Sample Initial
EDN
(ng/ml)
Added
EDN
(ng/ml)
Final
EDN
(ng/ml)
Measured
EDN
(ng/ml)
Recovered
EDN
(ng/ml)
Recovery (%)
1 4.0 2.0 6.0 6.1 2.1 105
4.0 8.0 7.6 3.6 90
8.0 12.0 11.5 7.5 94
2 5.5 2.0 7.5 7.6 2.1 105
4.0 9.5 9.7 4.2 105
8.0 13.5 13.3 7.8 98
3 11.5 2.0 13.5 13.3 1.8 90
4.0 15.5 15.2 3.7 93
8.0 19.5 20.2 8.7 109Predictive value of EDN levels for asthma
Predictive value of EDN levels for asthma was based on clinical
performanceresults (Table4).Using44.2ng/ml (medianþ1SD)as the
cut off for an elevated EDN level compared to those found in Controls,
sensitivity was 81.3%, speciﬁcity was 87.1%, positive predictive value
(PPV) was 90.7%, and negative predictive value (NPV) was 75.0%.Discussion
A direct comparison of serum EDN levels found using the Bio-
Tracer™ K®EDN ELISA Kit and the MBL EDN ELISA Kit showed a
clinically and statistically signiﬁcant correlation. The risks to pa-
tients in this study were no greater than those encountered in
routine medical practice and were small. Consequently, no serious
adverse events occurredduring the study.Medical beneﬁts for study
subjects included a more accurate understanding of the nature of
their underlying eosinophilic inﬂammation, which could possibly
lead to a more effective and timely treating of their asthma. Overall,
as this was an opportunity to formally vet the safety and efﬁcacy of
the recently developed BioTracer™ K® EDN ELISA Kit for the diag-
nosis, treatment, and monitoring of asthma, we believe the risk
beneﬁt ratio markedly favored the beneﬁcial aspects.
The BioTracer™ K® EDN ELISA Kit has two distinct advantages
over the MBL EDN ELISA Kit. First, it has a broader measuring range.
Due to the serum specimen dilution being twice what is performed
using the MBL Kit (10-fold dilution versus 5-fold dilution), EDN
measuring range of the BioTracer™ is 6e400 ng/ml versus
3e200 ng/ml. Theoretically, and in practice, asthma patients may
exhibit EDN levels >200 ng/ml, including one patient in this study.
Second, because of the greater dilution factor required for the
BioTracer™ K® EDN ELISA Kit as stated above, a smaller serum
specimen volume from the patient is required (20 ml versus 50 ml).
This is highly advantageous in young children because obtaining
adequate specimen volume is sometimes prevented by a child's
much lower total blood volume, difﬁculty in vein location, and their
unwillingness to cooperate with the venipuncture procedure.Table 4
Clinical performance.
Asthma groupy (n ¼ 48) Control group (n ¼ 31) Total (n ¼ 79)
Positivey 39 4 43
Negativey 9 27 36
Total 48 31 79
Sensitivity: 39/(39 þ 9) ¼ 81.3%, Speciﬁcity: 27/(27 þ 4) ¼ 87.1%, Positive Predictive
Value: 39/(39 þ 4) ¼ 90.7%, Negative Predictive Value: 27/(27 þ 9) ¼ 75.0%.
y Test results: BioTracer™ K® EDN ELISA.
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physiology (i.e., airway inﬂammation) for effective treatment;
however, many do not. Eosinophil granule proteins [EDN, ECP,
major basic protein (MBP), eosinophil peroxidase (EPO)] are the
most strongly implicated in asthma pathophysiology14 and EDN
and ECP are released almost exclusively by eosinophils.1 Therefore,
any change in EDN or ECP level would be a direct reﬂection of
changes in eosinophilic inﬂammation. In particular, several studies
have shown the efﬁcacy of EDN levels as a biomarker for eosin-
ophilic inﬂammation5e8 e including studies done by this research
group15e18 e not only for monitoring and treatment, but also for
diagnosis (e.g., asthma: PPV ¼ 93%, NPV ¼ 54%, sensitivity ¼ 66%,
speciﬁcity ¼ 89%).15 Though eosinophils are important as major
effector cells in asthma, eosinophil degranulation and its associ-
ated products like EDN may be even more important. It has been
suggested that the secretory activity of eosinophils e a combina-
tion of the concentration of eosinophils and their tendency to
release degranulation products e may be a key marker of disease
activity and is more accurately measured by eosinophil degranu-
lation products than by total eosinophil counts.4 This has been
demonstrated in two studies published by our research group15,17
and one by Kim et al.5 directly comparing EDN, ECP, and total
eosinophil counts to disease activity.
To measure EDN quickly, simply, and accurately, a commercial
EDN ELISA kit was developed by a Japanese research group,11 which
has been available for some time. EDN ELISA kits have demon-
strated accuracy in measuring EDN levels when compared to the
gold standard method of radioimmunoassay (RIA).11,19 Since
development, hundreds of studies have used theMBL EDN ELISA kit
for quick and accurate measurement of EDN. Indeed, when using
the MBL EDN ELISA Kit or BioTracer™ K® EDN ELISA Kit, serum EDN
measurement can be completed in under 2.5 h.11
Recently, the BioTracer™ K® EDN ELISA Kit was developed by Bio
Focus, Co., Ltd, in Korea. Its high accuracy, broad EDNmeasurement
range, and need for a much smaller patient specimen volume
would allow EDN measurements to be clinically useful and
economically practical for day-to-day diagnosis, treatment, and
monitoring of a number of eosinophil-related disorders such as
asthma, atopic dermatitis,11 and post-respiratory syncytial virus
(RSV) bronchiolitis recurrent wheezing.20
Because of its accuracy, complete lack of serious adverse events
when using it, and distinct advantages over the commercially
available MBL EDN ELISA Kit, we feel that the BioTracer™ K® EDN
ELISA Kit would be a useful and cost-effective tool in the diagnosis,
treatment, and monitoring of asthma.
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